Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

- At "AMWC SEA 2024," one of the world's top three aesthetic medicine congresses, the Nabota booth attracted over 500 visitors. - Educated over 300 Thai physicians on the innovative "Nabolift" technique through the "Nabota Master Class (NMC)." -...

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. No serious treatment related adverse events were reported and such findings were proportional between placebo and dosed groups. PK results support once a...

menu
menu